The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Drug-Resistant Tuberculosis—Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs
Abstract
Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. Following the declaration and the promotion in 1995 of directly observed treatment short course (DOTS), a cost-effective strategy to contain the tuberculosis epidemic, nearly 7 million lives have been saved compared with the pre-DOTS era, high cure rates have been achieved in most countries worldwide, and the global incidence of tuberculosis has been in a slow decline since the early 2000s. However, the emergence and spread of multidrug-resistant (MDR) tuberculosis, extensively drug-resistant (XDR) tuberculosis, and more recently, totally drug-resistant tuberculosis pose a threat to global tuberculosis control. Multidrug-resistant tuberculosis is a man-made problem. Laboratory facilities for drug susceptibility testing are inadequate in most tuberculosis-endemic countries, especially in Africa; thus diagnosis is missed, routine surveillance is not implemented, and the actual numbers of global drug-resistant tuberculosis cases have yet to be estimated. This exposes an ominous situation and reveals an urgent need for commitment by national programs to health system improvement because the response to MDR tuberculosis requires strong health services in general. Multidrug-resistant tuberculosis and XDR tuberculosis greatly complicate patient management within resource-poor national tuberculosis programs, reducing treatment efficacy and increasing the cost of treatment to the extent that it could bankrupt healthcare financing in tuberculosis-endemic areas. Why, despite nearly 20 years of WHO-promoted activity and >12 years of MDR tuberculosis-specific activity, has the country response to the drug-resistant tuberculosis epidemic been so ineffectual? The current dilemmas, unanswered questions, operational issues, challenges, and priority needs for global drug resistance screening and surveillance, improved treatment regimens, and management of outcomes and prevention of DR tuberculosis are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627
Cohn, D. L., Bustreo, F., & Raviglione, M. C. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.supplement_1.s121 · Cited by 340
Self-citation
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Self-citationThe WHO 2014 Global tuberculosis report—further to go
Zumla, A., George, A., Sharma, V., Herbert, R. H. N., Oxley, A., & Oliver, M. (2015) · The Lancet Global Health · doi:10.1016/s2214-109x(14)70361-4 · Cited by 434
Self-citationZhang, H., Li, D., Zhao, L., Fleming, J., Lin, N., Wang, T., Liu, Z., Li, C., Galwey, N., Deng, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2735 · Cited by 429
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Zumla, A. I., Gillespie, S. H., Hoelscher, M., Philips, P. P. J., Cole, S. T., Abubakar, I., McHugh, T. D., Schito, M., Maeurer, M., & Nunn, A. J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70328-1 · Cited by 342
Self-citation
Metadata
- Authors
- Zumla, A., Abubakar, I., Raviglione, M., Hoelscher, M., Ditiu, L., Mchugh, T. D., Squire, S. B., Cox, H., Ford, N., McNerney, R., Marais, B., Grobusch, M., Lawn, S. D., Migliori, G.-B., Mwaba, P., O’Grady, J., Pletschette, M., Ramsay, A., Chakaya, J., Schito, M., Swaminathan, S., Memish, Z., Maeurer, M., & Atun, R.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-15
- Volume
- 205
- Issue
- suppl_2
- Pages
- S228-S240
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2165898417
- Cited by
- 175
- References
- 3
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.